Phase 2 ARTEMIS-003 Trial: HS-20093 for mCRPC

/in , , /by

HS-20093  has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]

Read more

B7-H3 Emerges as Prime Target for Prostate Cancer Across All Stages

/in /by

A 2026 study published in Clinical Cancer Research has pinpointed B7-H3 as a standout therapeutic target for prostate cancer, offering hope against the disease’s toughest forms. The work analyzed tissue from prostate cancer patients across the full spectrum, from hormone-sensitive and castration-resistant to neuroendocrine and “double-negative” subtypes, revealing B7-H3’s consistent, broad expression. This uniformity stands […]

Read more

Phase 1 Study of BPX-601: A Controlled Immune Therapy for Advanced Prostate Cancer

/in , , /by

A new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]

Read more

Drugging the Undruggable: Million-Fold Leap Targets Prostate Cancer’s Elusive Androgen Receptor

/in /by

Prostate cancer treatments have hit a wall with castration-resistant cases, where tumors keep growing despite hormone blockers targeting the androgen receptor’s stable parts. A new study from University of British Columbia and BC Cancer researchers published on Nature cracks that open by hitting the receptor’s “undruggable” intrinsically disordered transactivation domain (NTD/TAD), the flexible region that […]

Read more

Newsletter 17/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Ok, the AACR 2026 meeting has passed, but in a month the ASCO 2026 annual meeting will begin. There will be new interesting research to share! Stay strong and fight on! As usual, we also have a podcast if […]

Read more

Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use

/in /by

A new analysis reports the development of a simple clinical score that may help physicians better identify which men are most likely to benefit from treatment with cabazitaxel after disease progression on earlier therapies. The work, based on a post-hoc analysis of the CABASTY study and validated in two major phase-3 trials, suggests that survival […]

Read more

B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages

/in /by

A new observational study of more than 8,000 prostate tumors shows that B7‑H3 (CD276) expression helps shape prognosis and could open new paths for targeted therapies. Researchers analyzed 8,157 prostate cancer samples with matched DNA and RNA data, stratifying them by tissue site, hormone‑sensitivity status, and self‑reported race, then examined how B7‑H3 levels related to […]

Read more

DNA Smart Drugs: Precision Cancer Treatment With a Double Lock

/in , /by

A new study in Nature Biotechnology describes a DNA-based drug system that can turn on only when it finds the right combination of markers on a cancer cell. This matters because many cancer drugs are powerful but also damage healthy tissue, so the main challenge is not only killing the tumor, but doing it with […]

Read more

Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC

/in , , /by

A novel double-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), called JANX014, has entered phase 1 testing in patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-human, open-label, multicenter trial, which dosed its initial participant in mid-April 2026, evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity through ascending intravenous doses administered as monotherapy to […]

Read more

Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors

/in , , , /by

PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]

Read more